We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 17, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S (NVO - Free Report) , Amgen Inc. (AMGN - Free Report) , Automatic Data Processing, Inc. (ADP - Free Report) , Equinor ASA (EQNR - Free Report) and Illinois Tool Works Inc. (ITW - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Novo Nordisk, Amgen and ADP
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, Amgen Inc. and Automatic Data Processing, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Novo Nordisk’s shares have gained +1.4% over the year-to-date basis against the Zacks Large-Cap Pharmaceuticals industry’s gain of +4.3%. The company’s promising diabetes drug, Ozempic, is off to a solid start since its launch. The drug remains the growth engine for the company.
The launch of Rybelsus also looks impressive. Novo Nordisk has one of the broadest diabetes portfolios in the industry. Drug sales have been gaining and maintaining momentum. Label expansion of the existing drugs is likely to boost sales.
However, lower realized prices in the United States, loss of exclusivity for products and stiff competition affect sales. Sales are also being negatively impacted by the COVID-19 pandemic. The supply challenges for Wegovy have hurts the stock. The patent expiry on some of the products in Novo Nordisk’s portfolio remains a woe.
Amgen’s shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+37.8% vs. -23.5%). The company’s key drugs like Prolia, Repatha and Xgeva are driving sales. New drugs Lumakras and Tezspire, are off to an encouraging start.
The acquisition of ChemoCentryx, if successfully closed, will add a strategic new growth asset in Tavneos to Amgen’s portfolio. Amgen boasts a strong biosimilars portfolio with potential new products expected to drive long-term growth.
However, increased pricing headwinds and competitive pressure are hurting sales of many of Amgen’s legacy products including some biosimilars. The IRS tax litigation is an overhang on Amgen shares. Estimates have declined slightly ahead of Q3 results. Amgen has a positive record of earnings surprise in recent quarters.
Shares of Automatic Data Processing have outperformed the Zacks Outsourcing industry over the past year (+7.0% vs. -2.0%). The company continues to enjoy a dominant position in the human capital management market through strategic buyouts like Celergo, WorkMarket, Global Cash Card and The Marcus Buckingham Company.
It has a strong business model, high recurring revenues, good margins, robust client retention and low capital expenditure. Further, it continues to innovate, improve operations and invest in its ongoing transformation efforts.
However, ADP faces significant competition in each of its product lines. Failure to remain technologically updated might reduce the demand for its solutions and services. Rising expenses due to investment in transformation efforts remains a concern. High debt remains a concern.
Other noteworthy reports we are featuring today include Equinor ASA and Illinois Tool Works Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works
For Immediate Release
Chicago, IL – November 17, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S (NVO - Free Report) , Amgen Inc. (AMGN - Free Report) , Automatic Data Processing, Inc. (ADP - Free Report) , Equinor ASA (EQNR - Free Report) and Illinois Tool Works Inc. (ITW - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Novo Nordisk, Amgen and ADP
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, Amgen Inc. and Automatic Data Processing, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Novo Nordisk’s shares have gained +1.4% over the year-to-date basis against the Zacks Large-Cap Pharmaceuticals industry’s gain of +4.3%. The company’s promising diabetes drug, Ozempic, is off to a solid start since its launch. The drug remains the growth engine for the company.
The launch of Rybelsus also looks impressive. Novo Nordisk has one of the broadest diabetes portfolios in the industry. Drug sales have been gaining and maintaining momentum. Label expansion of the existing drugs is likely to boost sales.
However, lower realized prices in the United States, loss of exclusivity for products and stiff competition affect sales. Sales are also being negatively impacted by the COVID-19 pandemic. The supply challenges for Wegovy have hurts the stock. The patent expiry on some of the products in Novo Nordisk’s portfolio remains a woe.
(You can read the full research report on Novo Nordisk here >>>)
Amgen’s shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+37.8% vs. -23.5%). The company’s key drugs like Prolia, Repatha and Xgeva are driving sales. New drugs Lumakras and Tezspire, are off to an encouraging start.
The acquisition of ChemoCentryx, if successfully closed, will add a strategic new growth asset in Tavneos to Amgen’s portfolio. Amgen boasts a strong biosimilars portfolio with potential new products expected to drive long-term growth.
However, increased pricing headwinds and competitive pressure are hurting sales of many of Amgen’s legacy products including some biosimilars. The IRS tax litigation is an overhang on Amgen shares. Estimates have declined slightly ahead of Q3 results. Amgen has a positive record of earnings surprise in recent quarters.
(You can read the full research report on Amgen here >>>)
Shares of Automatic Data Processing have outperformed the Zacks Outsourcing industry over the past year (+7.0% vs. -2.0%). The company continues to enjoy a dominant position in the human capital management market through strategic buyouts like Celergo, WorkMarket, Global Cash Card and The Marcus Buckingham Company.
It has a strong business model, high recurring revenues, good margins, robust client retention and low capital expenditure. Further, it continues to innovate, improve operations and invest in its ongoing transformation efforts.
However, ADP faces significant competition in each of its product lines. Failure to remain technologically updated might reduce the demand for its solutions and services. Rising expenses due to investment in transformation efforts remains a concern. High debt remains a concern.
(You can read the full research report on Automatic Data Processing here >>>)
Other noteworthy reports we are featuring today include Equinor ASA and Illinois Tool Works Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.